[go: up one dir, main page]

EA201791773A1 - Цистеиновая протеаза - Google Patents

Цистеиновая протеаза

Info

Publication number
EA201791773A1
EA201791773A1 EA201791773A EA201791773A EA201791773A1 EA 201791773 A1 EA201791773 A1 EA 201791773A1 EA 201791773 A EA201791773 A EA 201791773A EA 201791773 A EA201791773 A EA 201791773A EA 201791773 A1 EA201791773 A1 EA 201791773A1
Authority
EA
Eurasian Patent Office
Prior art keywords
igg
proteasis
cytestine
methods
polypeptide
Prior art date
Application number
EA201791773A
Other languages
English (en)
Other versions
EA035130B1 (ru
Inventor
Кристиан Челльман
София Ярнум
Эмма Нордаль
Original Assignee
Ханса Медикал Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханса Медикал Аб filed Critical Ханса Медикал Аб
Publication of EA201791773A1 publication Critical patent/EA201791773A1/ru
Publication of EA035130B1 publication Critical patent/EA035130B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)

Abstract

Настоящее изобретение относится к новому полипептиду, который проявляет активность цистеиновой протеазы в отношении IgG, и к его применениюи exПрименение полипептида включает способы профилактики или лечения заболеваний и состояний, опосредуемых IgG, и способы анализа IgG.
EA201791773A 2015-02-12 2016-02-12 Цистеиновая протеаза EA035130B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201502306A GB201502306D0 (en) 2015-02-12 2015-02-12 Protein
PCT/EP2016/053052 WO2016128558A1 (en) 2015-02-12 2016-02-12 Cysteine protease

Publications (2)

Publication Number Publication Date
EA201791773A1 true EA201791773A1 (ru) 2018-02-28
EA035130B1 EA035130B1 (ru) 2020-04-30

Family

ID=52781456

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791773A EA035130B1 (ru) 2015-02-12 2016-02-12 Цистеиновая протеаза

Country Status (23)

Country Link
US (4) US10696959B2 (ru)
EP (2) EP3256580B1 (ru)
JP (1) JP6961486B2 (ru)
KR (1) KR102524613B1 (ru)
CN (2) CN114231512B (ru)
AU (2) AU2016217800B2 (ru)
BR (1) BR112017017284A2 (ru)
CA (1) CA2976003A1 (ru)
CL (1) CL2017002065A1 (ru)
CO (1) CO2017009061A2 (ru)
DK (1) DK3256580T3 (ru)
EA (1) EA035130B1 (ru)
ES (1) ES2927234T3 (ru)
GB (1) GB201502306D0 (ru)
IL (1) IL253938B (ru)
LT (1) LT3256580T (ru)
MX (1) MX390806B (ru)
MY (1) MY188696A (ru)
PL (1) PL3256580T3 (ru)
PT (1) PT3256580T (ru)
SG (1) SG11201706346QA (ru)
WO (1) WO2016128558A1 (ru)
ZA (1) ZA201705113B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795973C1 (ru) * 2019-12-06 2023-05-15 Ридженерон Фармасьютикалз, Инк. Белковые композиции против vegf и способы их получения

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CA3094311A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
WO2019195423A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
AU2019247746B2 (en) 2018-04-03 2024-08-15 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
WO2020191300A1 (en) 2019-03-21 2020-09-24 Stridebio, Inc. Recombinant adeno-associated virus vectors
EP4038194A1 (en) 2019-10-04 2022-08-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
US11905523B2 (en) 2019-10-17 2024-02-20 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
WO2021112926A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2021163322A1 (en) 2020-02-14 2021-08-19 Ultragenyx Pharmaceutical Inc. Gene therapy for treating cdkl5 deficiency disorder
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
US12103960B2 (en) 2020-05-08 2024-10-01 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
GB202007434D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
JP2023529186A (ja) 2020-06-05 2023-07-07 上海宝済薬業有限公司 酵素とウィルスとの薬物組成物及びその使用
US20230364207A1 (en) * 2020-06-18 2023-11-16 Shanghai Bao Pharmaceuticals Co., Ltd. Mutant of immunoglobulin degrading enzyme idee
IL300717A (en) 2020-08-19 2023-04-01 Sarepta Therapeutics Inc ADENO-related virus vectors for the treatment of RETT syndrome
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
US20240189447A1 (en) 2021-04-16 2024-06-13 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
EP4384196A1 (en) 2021-08-11 2024-06-19 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
WO2023084095A2 (en) 2021-11-15 2023-05-19 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
KR20240123827A (ko) 2021-12-16 2024-08-14 상하이 바오 파마슈티컬스 컴퍼니 리미티드 항면역글로불린 분해 효소에 의해 효소 절단된 Fc 변이체
TW202334183A (zh) 2021-12-22 2023-09-01 大陸商上海寶濟藥業有限公司 免疫球蛋白降解酶ｌｄｅＥ的突變體的用途
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN118853710A (zh) * 2022-11-08 2024-10-29 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
US12129499B2 (en) 2023-01-06 2024-10-29 Seismic Therapeutic, Inc. Protease variants and uses thereof
WO2025072144A1 (en) * 2023-09-27 2025-04-03 Osprey Biopharmaceuticals, Inc. Polypeptides having human igg cleavage activity

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
AU2002216863B8 (en) 2000-12-21 2008-03-20 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
AU2003284441A1 (en) * 2002-11-29 2004-06-23 Morinaga Milk Industry Co., Ltd. Protease inhibitor
DE602004022923D1 (de) * 2003-03-04 2009-10-15 Intercell Ag Streptococcus pyogenes antigene
AU2006256891B2 (en) * 2005-06-09 2011-08-04 Hansa Biopharma AB Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
US7544577B2 (en) * 2005-08-26 2009-06-09 International Business Machines Corporation Mobility enhancement in SiGe heterojunction bipolar transistors
US8323908B2 (en) 2007-09-14 2012-12-04 Genovis Ab Method of assessing glycosylation state or functional quality of an IgG containing sample
WO2009075646A1 (en) 2007-12-13 2009-06-18 Bengt Guss Improved immunizing composition
CA2709029A1 (en) 2007-12-21 2009-07-02 Bianca Eser Stability testing of antibodies
CN102308216B (zh) * 2009-02-09 2014-07-09 罗切格利卡特公司 免疫球蛋白糖基化模式分析
ES2612520T3 (es) 2010-05-26 2017-05-17 Intervacc Ab Vacuna contra infecciones estreptocócicas basada en proteínas recombinantes
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
CN103214549B (zh) * 2013-01-15 2015-08-05 珠海市丽珠单抗生物技术有限公司 一种还原免疫球蛋白的方法及其试剂盒
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795973C1 (ru) * 2019-12-06 2023-05-15 Ридженерон Фармасьютикалз, Инк. Белковые композиции против vegf и способы их получения

Also Published As

Publication number Publication date
PL3256580T3 (pl) 2022-11-28
WO2016128558A1 (en) 2016-08-18
MY188696A (en) 2021-12-23
IL253938A0 (en) 2017-10-31
US20180023070A1 (en) 2018-01-25
NZ733959A (en) 2024-07-26
CN114231512B (zh) 2025-02-14
EP3256580B1 (en) 2022-07-06
AU2016217800A1 (en) 2017-08-10
US11214784B2 (en) 2022-01-04
AU2016217800B2 (en) 2021-08-12
SG11201706346QA (en) 2017-09-28
CN114231512A (zh) 2022-03-25
JP6961486B2 (ja) 2021-11-05
PT3256580T (pt) 2022-10-03
EP4108768A1 (en) 2022-12-28
US11667905B2 (en) 2023-06-06
GB201502306D0 (en) 2015-04-01
CN107532156A (zh) 2018-01-02
MX2017010390A (es) 2017-12-07
DK3256580T3 (en) 2022-10-03
JP2018506286A (ja) 2018-03-08
KR102524613B1 (ko) 2023-04-21
CL2017002065A1 (es) 2018-04-02
LT3256580T (lt) 2022-10-10
US10696959B2 (en) 2020-06-30
MX390806B (es) 2025-03-21
KR20170116137A (ko) 2017-10-18
US12359183B2 (en) 2025-07-15
ES2927234T3 (es) 2022-11-03
ZA201705113B (en) 2024-01-31
US20200283749A1 (en) 2020-09-10
BR112017017284A2 (pt) 2018-04-17
IL253938B (en) 2020-01-30
AU2021266293A1 (en) 2021-12-09
EA035130B1 (ru) 2020-04-30
US20220170004A1 (en) 2022-06-02
EP3256580A1 (en) 2017-12-20
AU2021266293B2 (en) 2024-10-03
US20230357741A1 (en) 2023-11-09
CO2017009061A2 (es) 2018-01-16
CA2976003A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
EA201791773A1 (ru) Цистеиновая протеаза
EA201791775A1 (ru) Цистеиновая протеаза
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
EA201990033A1 (ru) Вариантные аденоассоциированные вирусы и способы их применения
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790922A1 (ru) Ингибиторы бромодомена
EA201691974A1 (ru) Антитела против ox40 и способы их применения
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201691541A1 (ru) Новые анти-baff антитела
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
BR112017015880A2 (pt) anticorpos, usos e métodos

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM